Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuzZYNKSzVyPUCuNFAxPDV6IH7N M2fHfHNCVkeHUh?=
ES4 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Ec45KSzVyPUCuNFAxPjV|IH7N M33oXnNCVkeHUh?=
ACHN MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon1TWM2OD1yLkCwNFg5PyCwTR?= MX;TRW5ITVJ?
KYSE-510 NX3wN21ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHxOGlqUUN3ME2wMlAxODl5NTDuUS=> MXTTRW5ITVJ?
EW-7 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInsWGJKSzVyPUCuNFAzPThibl2= NF;DPW5USU6JRWK=
BFTC-905 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHNOnhlUUN3ME2wMlAxPTF3IH7N M2m0VnNCVkeHUh?=
KE-37 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEC1OlEhdk1? MXnTRW5ITVJ?
SBC-5 NHvvNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXGeG9KSzVyPUCuNFA2PyCwTR?= NHq2fYlUSU6JRWK=
NKM-1 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEC3NFkhdk1? M{PIPXNCVkeHUh?=
RH-1 M{jBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEC3NVghdk1? M{O4N3NCVkeHUh?=
ALL-PO NHn4WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuxcpNKSzVyPUCuNFA5OyCwTR?= NH3UWm1USU6JRWK=
QIMR-WIL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPKTWM2OD1yLkCwPFk1KG6P M3y0SHNCVkeHUh?=
A375 M1npbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEC5PVUhdk1? MXXTRW5ITVJ?
SIG-M5 M1\2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP0TWM2OD1yLkCxNFQhdk1? MWPTRW5ITVJ?
KGN M4LrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETFZ4ZKSzVyPUCuNFExQCCwTR?= MmPBV2FPT0WU
EW-13 NH7kVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjtOnE5UUN3ME2wMlAyOTJibl2= NEmzZoVUSU6JRWK=
NCI-SNU-1 NFvWPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXsSGNJUUN3ME2wMlAyPiCwTR?= MXfTRW5ITVJ?
PSN1 M4Tre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEG2OUBvVQ>? MYDTRW5ITVJ?
HUTU-80 NV;oUWh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zeG04UUN3ME2wMlAyPjZibl2= NVPlZZV7W0GQR1XS
EW-16 NE\KbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCxO5pzUUN3ME2wMlAzOyCwTR?= MYXTRW5ITVJ?
786-0 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEKzJI5O MXLTRW5ITVJ?
ES1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPISJhKSzVyPUCuNFI3QCCwTR?= M4rxSXNCVkeHUh?=
RKO MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLnflA1UUN3ME2wMlAzPzlibl2= NH7lZ49USU6JRWK=
ESS-1 NXzyR49sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfqTWM2OD1yLkCyPFYhdk1? NY\PWYVCW0GQR1XS
SK-UT-1 NX;JUmp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvtOVFKSzVyPUCuNFI6PyCwTR?= M3X1[HNCVkeHUh?=
LB2241-RCC M1TVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEOxPEBvVQ>? M3HUSXNCVkeHUh?=
CHL-1 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\lVmlEPTB;MD6wN|I1KG6P MojCV2FPT0WU
SW1783 NGTUVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn31TWM2OD1yLkCzN|Yhdk1? MWPTRW5ITVJ?
MEL-JUSO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEO5NUBvVQ>? MWLTRW5ITVJ?
HT-29 M4T0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nPfGlEPTB;MD6wOFE{KG6P NGX4WZlUSU6JRWK=
SNG-M Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMESyOUBvVQ>? MXjTRW5ITVJ?
TE-15 M4n1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nFOGlEPTB;MD6wOFY1KG6P NYnrb4tZW0GQR1XS
HOS M2HXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO0OJhKSzVyPUCuNFQ5KG6P MnHTV2FPT0WU
BB65-RCC NV\5RYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMEWxNkBvVQ>? MXfTRW5ITVJ?
HCE-4 NGq1[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEWyPEBvVQ>? Mn\vV2FPT0WU
MHH-ES-1 M1zYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEWzNUBvVQ>? MmC4V2FPT0WU
RPMI-7951 M{XCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEW0NUBvVQ>? NIHYW4JUSU6JRWK=
IST-SL2 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH4[olKSzVyPUCuNFU5PCCwTR?= NGTtU4lUSU6JRWK=
CMK M4P2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTWTWM2OD1yLkC1PFYhdk1? MX3TRW5ITVJ?
GR-ST Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDK[oNTUUN3ME2wMlA2QTVibl2= NXPNdWduW0GQR1XS
NALM-6 NFTiNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fXT2lEPTB;MD6wOlIzKG6P MWDTRW5ITVJ?
RPMI-6666 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK3eHhpUUN3ME2wMlA3PTJibl2= M1HBfnNCVkeHUh?=
LC-2-ad NIPKd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDPTWM2OD1yLkC2OVMhdk1? MnW0V2FPT0WU
ARH-77 NULWSJg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33XNWlEPTB;MD6wO|EyKG6P M2rwVXNCVkeHUh?=
IST-MEL1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jNSmlEPTB;MD6wO|I3KG6P M{G2[XNCVkeHUh?=
SW1710 NYLUdoV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFexfGNKSzVyPUCuNFc2OSCwTR?= NEH5S|ZUSU6JRWK=
DEL NGTGeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ZTWM2OD1yLkC4PFchdk1? NEPwcXFUSU6JRWK=
AGS MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjWXGRKSzVyPUCuNFkxOiCwTR?= NE\NZlBUSU6JRWK=
NCI-H2122 NEG0UXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEm0OkBvVQ>? NH70eG5USU6JRWK=
HSC-4 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUCyJI5O MYDTRW5ITVJ?
AM-38 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonmTWM2OD1yLkGyNUBvVQ>? MYTTRW5ITVJ?
769-P Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofCTWM2OD1yLkGyN{BvVQ>? MWjTRW5ITVJ?
RT-112 NUDsT2VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL2N|U6UUN3ME2wMlEzPyCwTR?= M4XvR3NCVkeHUh?=
MCF7 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMUO2JI5O M2TJUXNCVkeHUh?=
IGROV-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\zZ|ZRUUN3ME2wMlE1PSCwTR?= MnzwV2FPT0WU
OCI-AML2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{noOGlEPTB;MD6xOFchdk1? NFLJdHBUSU6JRWK=
NCI-H1299 NIS3WYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTnTWM2OD1yLkG1O{BvVQ>? NXLzb|ltW0GQR1XS
A431 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;yTWM2OD1yLkG4N{BvVQ>? NVfnUnE3W0GQR1XS
SW982 M{W5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvxeIVrUUN3ME2wMlIyOyCwTR?= NYDTd4V4W0GQR1XS
BB30-HNC NUfaVnVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3yNHZKSzVyPUCuNlMyKG6P NUKxUY9WW0GQR1XS
ACN MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojCTWM2OD1yLkK0OEBvVQ>? NYW3d4E1W0GQR1XS
647-V NYLXTXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW1fVFKSzVyPUCuNlQ5KG6P MkTYV2FPT0WU
SK-PN-DW MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMk[2JI5O M{LVbHNCVkeHUh?=
LCLC-97TM1 M2n1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\C[olKSzVyPUCuNlY4KG6P MlLCV2FPT0WU
LB1047-RCC Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXrOJhKSzVyPUCuNlY6KG6P NYTT[Yo3W0GQR1XS
A2780 M{C3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMkegcm0> M{i2[3NCVkeHUh?=
C-33-A M2izW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLaTWM2OD1yLkK3N{BvVQ>? NYDSXGVUW0GQR1XS
NCI-H2228 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYizNHZzUUN3ME2wMlMyPCCwTR?= MY\TRW5ITVJ?
TE-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXGbWVKSzVyPUCuN|E3KG6P MXzTRW5ITVJ?
HC-1 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HiSWlEPTB;MD6zNlchdk1? MXPTRW5ITVJ?
SK-MES-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX5U4RKSzVyPUCuN|I5KG6P MYDTRW5ITVJ?
NCI-H1355 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnNNpRKSzVyPUCuN|gyKG6P MV\TRW5ITVJ?
YKG-1 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDFXoJKSzVyPUCuOFE6KG6P M4i3VnNCVkeHUh?=
RS4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYmxOZYxUUN3ME2wMlQ{OyCwTR?= MmHEV2FPT0WU
Daoy M3zsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHU[mFzUUN3ME2wMlQ2PiCwTR?= M1TKOHNCVkeHUh?=
A3-KAW NVfUUJIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvtbmhCUUN3ME2wMlU2OSCwTR?= MYPTRW5ITVJ?
SK-MEL-30 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLWTWM2OD1yLkW1OEBvVQ>? NWPTN5BpW0GQR1XS
U031 NHi2cGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;xfYtKSzVyPUCuOVY2KG6P NWG5UY5JW0GQR1XS
SK-LMS-1 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrJbYFjUUN3ME2wMlU4QCCwTR?= NH;VPItUSU6JRWK=
ES6 NFvaNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPzT4E6UUN3ME2wMlU5PiCwTR?= NF3xU41USU6JRWK=
EoL-1-cell MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITkO4RKSzVyPUCuOlE3KG6P NXXzRnZTW0GQR1XS
NCI-H2009 NVK0eWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnKO3FKSzVyPUCuOlE6KG6P M3HFT3NCVkeHUh?=
A4-Fuk NEXJ[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNkK2JI5O M4nVR3NCVkeHUh?=
KYSE-270 M2PZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn4TWM2OD1yLk[zOEBvVQ>? M4DHOXNCVkeHUh?=
SK-LU-1 NYfscI5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXewe3Z{UUN3ME2wMlY2PSCwTR?= MmftV2FPT0WU
SW872 NFfpWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nNfGlEPTB;MD63OlUhdk1? M4G0VHNCVkeHUh?=
ES8 NHS0SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X5U2lEPTB;MD63PEBvVQ>? M2i4cnNCVkeHUh?=
G-402 NWn1[VF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW5TWM2OD1yLke4OEBvVQ>? NGXhRmpUSU6JRWK=
ATN-1 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHKO2NEUUN3ME2wMlgxPyCwTR?= Mk\pV2FPT0WU
DoTc2-4510 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zzd2lEPTB;MD65NFEhdk1? NF24UGFUSU6JRWK=
MES-SA NXX2U3UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwOUC1JI5O NWnmRYVXW0GQR1XS
SF268 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TsSWlEPTB;MD65Nlchdk1? M1TibnNCVkeHUh?=
SF539 NVHzR2NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjSVFdKSzVyPUGuNFIhdk1? M3;3WnNCVkeHUh?=
NB69 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj2VGFKSzVyPUGuNFUhdk1? NVO5T3VmW0GQR1XS
8505C NYfCZWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwME[gcm0> NFf2RoRUSU6JRWK=
CAL-12T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TmOGlEPTB;MT6wPEBvVQ>? NHK4So9USU6JRWK=
BHY NGfnSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInDfpNKSzVyPUGuNVQhdk1? M1Ln[HNCVkeHUh?=
LB647-SCLC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnmVHJKSzVyPUGuNVghdk1? M{TycnNCVkeHUh?=
CAL-62 M{fMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzUTZBKSzVyPUGuNlIhdk1? MlWzV2FPT0WU
MEG-01 NWrETZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHTWM2OD1zLkK3JI5O M4G1N3NCVkeHUh?=
MG-63 M4fGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwM{Ogcm0> MmHRV2FPT0WU
SW620 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwM{Wgcm0> NEDw[nBUSU6JRWK=
A388 NUjmcJk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DLcGlEPTB;MT6zOkBvVQ>? MUjTRW5ITVJ?
BCPAP NIDHUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn5dINKSzVyPUGuOFUhdk1? NWjVeI1lW0GQR1XS
P30-OHK NWrMVY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILYZYJKSzVyPUGuOFYhdk1? MX3TRW5ITVJ?
Ca9-22 NHjLVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\GS|FbUUN3ME2xMlU1KG6P MV\TRW5ITVJ?
VMRC-RCZ M2nKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33kSmlEPTB;MT61OEBvVQ>? M{HvWHNCVkeHUh?=
LOXIMVI MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYroSJpbUUN3ME2xMlYhdk1? MkHMV2FPT0WU
L-540 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHSZWRKSzVyPUGuOkBvVQ>? MWnTRW5ITVJ?
NTERA-S-cl-D1 M2WzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7zWnRTUUN3ME2xMlY1KG6P Mn3nV2FPT0WU
MFH-ino NXjxdI0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\lTWM2OD1zLk[2JI5O NHrsZYNUSU6JRWK=
Calu-6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDSTWM2OD1zLkezJI5O MojBV2FPT0WU
HEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwN{mgcm0> M4DrXXNCVkeHUh?=
CAL-33 NFXSZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqxN21PUUN3ME2xMlg6KG6P NGX1PGdUSU6JRWK=
HSC-3 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwOUGgcm0> MUDTRW5ITVJ?
KU812 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwOUGgcm0> NGKyVY9USU6JRWK=
EB2 NWq2SXEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOybFBTUUN3ME2yMlAyKG6P M{P1TnNCVkeHUh?=
SR MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJwMUKgcm0> MnvPV2FPT0WU
NCI-H2087 NEW0RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KyZ2lEPTB;Mj6xOEBvVQ>? NWDmfm9LW0GQR1XS
H4 M1OwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILQblJKSzVyPUKuNVghdk1? NXzY[4FPW0GQR1XS
EW-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfBWJBOUUN3ME2yMlIzKG6P NWH6d5pGW0GQR1XS
MC-IXC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwMk[gcm0> MUDTRW5ITVJ?
NCI-H727 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnniTWM2OD1{LkWxJI5O MlrTV2FPT0WU
MRK-nu-1 M2TpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiwSVV4UUN3ME2yMlU4KG6P MnXkV2FPT0WU
COLO-668 NHn3cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPWWnRFUUN3ME2yMlY3KG6P NVnwWGRkW0GQR1XS
CGTH-W-1 NH\nWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwN{Kgcm0> NF3zcGNUSU6JRWK=
CHP-212 NUDxPWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrpZopIUUN3ME2yMlc2KG6P MX\TRW5ITVJ?
GI-1 NXX1fnhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L2NmlEPTB;Mj63OkBvVQ>? MY\TRW5ITVJ?
HCC1806 NGXMVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwOUGgcm0> Mn;DV2FPT0WU
HLE M1WyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHPTWM2OD1|IH7N MYnTRW5ITVJ?
HSC-2 NFTTO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\KTWM2OD1|LkCzJI5O NUnoNnE5W0GQR1XS
DMS-273 NUL0SG5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD1TWM2OD1|LkC3JI5O MWnTRW5ITVJ?
DU-4475 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e4WWlEPTB;Mz6xOEBvVQ>? MoLsV2FPT0WU
LXF-289 M{nGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTrTWM2OD1|LkOxJI5O NWjqNJFxW0GQR1XS
PANC-03-27 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj5enVKUUN3ME2zMlUyKG6P NGjNd5RUSU6JRWK=
GAMG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jFbGlEPTB;Mz63OEBvVQ>? NGPz[IJUSU6JRWK=
NCI-H522 NFfqeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe5bGQ{UUN3ME20MlM1KG6P M1q2b3NCVkeHUh?=
SW626 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDkTWM2OD12LkS2JI5O MX;TRW5ITVJ?
HT-144 NI[3eIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRwOUKgcm0> NI\pWWtUSU6JRWK=
MEL-HO MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKxV2kyUUN3ME21MlE3KG6P M4HiZnNCVkeHUh?=
BE-13 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33abWlEPTB;NT6yNUBvVQ>? NV\IbYFWW0GQR1XS
VA-ES-BJ MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP0dohKSzVyPUWuNlYhdk1? NFrHS3VUSU6JRWK=
NCI-H441 NF3rfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrzd3lKSzVyPUWuOkBvVQ>? Mn3RV2FPT0WU
KP-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjRN5ZKSzVyPUWuOlEhdk1? MVHTRW5ITVJ?
LoVo M3HNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTVwN{Ggcm0> MnrBV2FPT0WU
HT-1080 NWC0e2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonITWM2OD13LkizJI5O NIG3e5hUSU6JRWK=
GB-1 NWPtOo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PXfWlEPTB;NT64OEBvVQ>? MonNV2FPT0WU
IA-LM MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HLTWlEPTB;NT65NUBvVQ>? M1fnc3NCVkeHUh?=
8-MG-BA M4fMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO5Z3pLUUN3ME21Mlk{KG6P NITyXndUSU6JRWK=
SK-HEP-1 M33ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwMUSgcm0> NX7aZ2J6W0GQR1XS
697 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[xU2lEPTB;Nj6yOUBvVQ>? NFqwS5hUSU6JRWK=
KYSE-450 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTZwM{Kgcm0> Ml:xV2FPT0WU
HCC2998 M3nXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXmUlhKSzVyPU[uN|Qhdk1? NFPDdFNUSU6JRWK=
HD-MY-Z MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH2[YJKSzVyPU[uOlghdk1? M{OyOnNCVkeHUh?=
OS-RC-2 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomyTWM2OD14Lk[4JI5O MX;TRW5ITVJ?
SF126 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWzUWZPUUN3ME23MlA2KG6P MonvV2FPT0WU
Ca-Ski NIqwNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTdwMEmgcm0> NFLOOVBUSU6JRWK=
NCI-H358 M2\neGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTdwMU[gcm0> M1rpfXNCVkeHUh?=
J82 NH;l[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SyPGlEPTB;Nz60NUBvVQ>? M2jwSXNCVkeHUh?=
NCI-H2342 NX7OeFNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTHTWM2OD15Lk[zJI5O NIXkOY5USU6JRWK=
OVCAR-8 NXfIfnppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXMdJNKSzVyPUeuPUBvVQ>? NGXER4lUSU6JRWK=
TE-8 M2Lh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13ITmlEPTB;ODDuUS=> M2XBS3NCVkeHUh?=
ETK-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRThwMEigcm0> NUHLZWlIW0GQR1XS
HAL-01 NXjRZnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\HbGlEPTB;OD6yJI5O NVzPfplUW0GQR1XS
KYSE-150 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LCdWlEPTB;OD60O{BvVQ>? Mmq0V2FPT0WU
NCI-H810 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTF[4RMUUN3ME24MlU3KG6P M3TwWHNCVkeHUh?=
ONS-76 M2LJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrtTWM2OD16Lk[4JI5O M4XKZXNCVkeHUh?=
NMC-G1 NELXW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjGTWM2OD16Lke2JI5O NYHVNGptW0GQR1XS
C3A NIPBcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILCOoxKSzVyPUiuPFQhdk1? NIjhU4FUSU6JRWK=
PA-1 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRThwOUmgcm0> MnLrV2FPT0WU
SH-4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC5PJBKSzVyPUmuNFIhdk1? NEHTRY9USU6JRWK=
EFO-27 M2TWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD5RnByUUN3ME25MlA2KG6P MXHTRW5ITVJ?
CAPAN-1 NFza[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[wVmlEPTB;OT6yN{BvVQ>? M4TVWXNCVkeHUh?=
DU-145 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHSOo9zUUN3ME25MlI6KG6P M4e4SnNCVkeHUh?=
A101D NEXESXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzTdmRKSzVyPUmuN|chdk1? NWP1S2NWW0GQR1XS
ST486 NFzQZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTlwNEGgcm0> M3TSeHNCVkeHUh?=
NCI-H1437 NWnMSVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLZXm1KSzVyPUmuOFIhdk1? NFHHTJNUSU6JRWK=
HGC-27 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrlV29KSzVyPUmuOkBvVQ>? MWLTRW5ITVJ?
8305C Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i5cmlEPTB;OT62OEBvVQ>? M{S0TXNCVkeHUh?=
OCUB-M NHjtXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDR[VZKSzVyPUGwMlA{KG6P NY\rSYZQW0GQR1XS
COLO-679 NU\NNVNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q4VmlEPTB;MUCuNFchdk1? MY\TRW5ITVJ?
Detroit562 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFyLkSyJI5O NHq0cppUSU6JRWK=
A204 NEfHcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXzUnZKSzVyPUGxMlE3KG6P M3P6d3NCVkeHUh?=
NCI-H1734 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD2TWM2OD1zMT6yPUBvVQ>? M4DxR3NCVkeHUh?=
MC-CAR NVX0OId4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n5b2lEPTB;MUGuOVghdk1? NFntdlRUSU6JRWK=
NCI-H2170 NV6zT4tUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr0WYRJUUN3ME2xNU46PyCwTR?= NWLtZ2t7W0GQR1XS
NCI-SNU-5 NVnFUIJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jKdmlEPTB;MUKuNVMhdk1? M2Tjd3NCVkeHUh?=
HCE-T MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF75fVlKSzVyPUGyMlQzKG6P NWKzPZRMW0GQR1XS
KYSE-180 MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF{LkixJI5O MXXTRW5ITVJ?
C8166 NGH0RldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDYS3d7UUN3ME2xN{4xQCCwTR?= NWj1XGtMW0GQR1XS
NCI-H460 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfHTWM2OD1zMz61OEBvVQ>? NWLmUWVDW0GQR1XS
SNU-449 M4XuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfwc4hTUUN3ME2xN{44PyCwTR?= M3vyb3NCVkeHUh?=
MDA-MB-468 NF7HNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn21TWM2OD1zND6xNkBvVQ>? NWC5eIxpW0GQR1XS
COR-L23 NVXlZmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq5N2hEUUN3ME2xOE4yOyCwTR?= NH3uSmNUSU6JRWK=
CTV-1 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXIeGJKSzVyPUG0MlE1KG6P MUfTRW5ITVJ?
BL-41 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTmTWM2OD1zND6zO{BvVQ>? NUC0SoZkW0GQR1XS
IGR-1 NUPUXZN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPWTWM2OD1zND60NkBvVQ>? MVzTRW5ITVJ?
TK10 M2rTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX30V5Z{UUN3ME2xOE41QSCwTR?= NFjqeZBUSU6JRWK=
REH MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3CRlRsUUN3ME2xOE42OSCwTR?= MmDIV2FPT0WU
LU-139 NUTOPIFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfkelRkUUN3ME2xOE42QSCwTR?= MX3TRW5ITVJ?
KP-N-YS NEGwdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nuc2lEPTB;MUSuPVchdk1? M{XMcXNCVkeHUh?=
PANC-10-05 M3T6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD1zNT6zPEBvVQ>? NVz0RmJjW0GQR1XS
HL-60 NWHCTXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHmRXlKUUN3ME2xOU43QSCwTR?= NF\q[XFUSU6JRWK=
T84 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f4N2lEPTB;MUWuPVYhdk1? MlP5V2FPT0WU
RPMI-8226 NWj5bndYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXVVolLUUN3ME2xOk4xOiCwTR?= Mkj5V2FPT0WU
UM-UC-3 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\BSIZvUUN3ME2xOk4yPiCwTR?= Mn;qV2FPT0WU
TE-10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\YdWlEPTB;MU[uNlEhdk1? NVvYSplJW0GQR1XS
CAL-148 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S5NWlEPTB;MUeuNlMhdk1? NELKOI5USU6JRWK=
BV-173 NGmxV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL3XGZKSzVyPUG3MlI4KG6P MVnTRW5ITVJ?
Calu-3 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjSbotFUUN3ME2xO{4zQSCwTR?= NIjlW5FUSU6JRWK=
RPMI-2650 NGfPRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjG[VV3UUN3ME2xO{42QSCwTR?= M4fCeHNCVkeHUh?=
MKN45 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTNTWM2OD1zNz63N{BvVQ>? NYrvSJh6W0GQR1XS
NUGC-3 NVnhNphjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nUeGlEPTB;MUiuN|Qhdk1? NIjlfFZUSU6JRWK=
NCI-H520 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TUcGlEPTB;MUiuO|chdk1? NEHsN2tUSU6JRWK=
CCRF-CEM M2rNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF6Lki1JI5O NXrUbopjW0GQR1XS
NCI-H2405 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnNPIdVUUN3ME2xPU4yKG6P NXT5OI5JW0GQR1XS
ES7 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF7Lke2JI5O M2TWT3NCVkeHUh?=
BPH-1 NGPIcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXGbZJNUUN3ME2yNE4zQCCwTR?= NVH2OZBbW0GQR1XS
SAS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C0VWlEPTB;MkCuOUBvVQ>? MmPLV2FPT0WU
HuCCT1 NWC0RWJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nKR2lEPTB;MkCuOVghdk1? NYrKd2xYW0GQR1XS
LOUCY NFnsfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDVSVY1UUN3ME2yNE43PiCwTR?= MlLnV2FPT0WU
NCI-H292 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnFbW1wUUN3ME2yNE44QSCwTR?= MljEV2FPT0WU
G-361 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrkfXExUUN3ME2yNU4xPyCwTR?= NEfxRYdUSU6JRWK=
M059J MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJzLkC4JI5O MY\TRW5ITVJ?
NCI-H1651 M3u1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJzLkGxJI5O NYnKWotXW0GQR1XS
KALS-1 NH:x[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJzLkO5JI5O NHTCWWJUSU6JRWK=
DJM-1 NHXifG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHeyO5VKSzVyPUKxMlU6KG6P MmDZV2FPT0WU
AU565 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq0TWM2OD1{MT64N{BvVQ>? NGjENJhUSU6JRWK=
HCC38 NUm1VmhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;VSnNKSzVyPUKxMlk2KG6P NYjkSFJpW0GQR1XS
U251 NXXVNXIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL1b4ppUUN3ME2yNk4zPyCwTR?= NGCycnNUSU6JRWK=
ABC-1 M{Hkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnUXXRKSzVyPUKyMlY2KG6P MUDTRW5ITVJ?
SK-NEP-1 NUL6OWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ{LkmzJI5O M4jJeHNCVkeHUh?=
CESS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ|LkG5JI5O MUTTRW5ITVJ?
MIA-PaCa-2 M1KxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ|LkO2JI5O M2nqVnNCVkeHUh?=
SUP-T1 NEewOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLVN2ZNUUN3ME2yN{41PyCwTR?= MkX3V2FPT0WU
L-428 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG0boZoUUN3ME2yN{43OiCwTR?= M37UOHNCVkeHUh?=
SW954 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3aTWM2OD1{Mz62PEBvVQ>? NVjYZWVlW0GQR1XS
HO-1-N-1 NFzNXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ|Lke3JI5O NVHhNoFPW0GQR1XS
CHP-126 NYPXW4MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ2LkG0JI5O Ml34V2FPT0WU
HMV-II MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TWVmlEPTB;MkSuN|Qhdk1? NUDyeXZIW0GQR1XS
NB10 NYPqS2w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ2LkO3JI5O NULRcZJbW0GQR1XS
A172 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WzTWlEPTB;MkSuO|Ehdk1? M1L4bnNCVkeHUh?=
MONO-MAC-6 NGrNWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTaXmdKSzVyPUK0Mlg1KG6P NFrOXGRUSU6JRWK=
NCI-H1650 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[0dJo3UUN3ME2yOU41KG6P M1TR[HNCVkeHUh?=
NH-12 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\z[IdsUUN3ME2yOU42KG6P M13vWnNCVkeHUh?=
ML-2 NHv4eY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\jTWM2OD1{NT63OEBvVQ>? MV;TRW5ITVJ?
MZ2-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPLTWM2OD1{Nj6yNkBvVQ>? MV3TRW5ITVJ?
COLO-684 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ZTWM2OD1{Nj60NUBvVQ>? M3;yZnNCVkeHUh?=
HuP-T4 NHrHTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYro[ohDUUN3ME2yO{4{KG6P M2LCd3NCVkeHUh?=
SW837 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT2fZVKSzVyPUK3MlYzKG6P M{G1UnNCVkeHUh?=
MDA-MB-231 NFzmdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ5Lke4JI5O NWDqWZVuW0GQR1XS
KYSE-140 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXoTWM2OD1{Nz65NUBvVQ>? NGLab5BUSU6JRWK=
NOMO-1 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDNTWM2OD1{OD62PEBvVQ>? M2XEbXNCVkeHUh?=
GP5d NXvyPFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPyTWM2OD1{OD63NkBvVQ>? MlXqV2FPT0WU
COR-L105 M1PmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\W[2lEPTB;MkmuOFIhdk1? NHu1T5ZUSU6JRWK=
LS-411N M3XuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHMendKSzVyPUK5Mlg5KG6P MmjjV2FPT0WU
NY M2nWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXzTWM2OD1|MD6xPEBvVQ>? MkPOV2FPT0WU
NCI-H2030 M{X3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrZVYNKSzVyPUOwMlQ2KG6P NWHxdFdpW0GQR1XS
CCF-STTG1 NULWPHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCzTWM2OD1|MT60NkBvVQ>? M2HwSHNCVkeHUh?=
NCI-H1703 NE\q[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTPUWlKSzVyPUOxMlc5KG6P M3LVVnNCVkeHUh?=
TUR MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XVcmlEPTB;M{KuNFMhdk1? MoPvV2FPT0WU
NOS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[wWohKSzVyPUOyMlQ1KG6P NYmwTpZvW0GQR1XS
A2058 M{fZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTN{LkizJI5O M2\LNnNCVkeHUh?=
LCLC-103H MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rx[WlEPTB;M{OuNlUhdk1? NVWwfIY4W0GQR1XS
NCI-H510A M{DacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTuSZhKUUN3ME2zN{4zPyCwTR?= NGfG[ZBUSU6JRWK=
BC-1 NUXZNHhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vq[mlEPTB;M{OuO|chdk1? NWXXc5JHW0GQR1XS
SK-CO-1 NGnQ[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN2LkCxJI5O NEDkeopUSU6JRWK=
A673 M3Taemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknBTWM2OD1|ND6xO{BvVQ>? Ml\OV2FPT0WU
VM-CUB-1 NVL5cI55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHsXINDUUN3ME2zOE43QSCwTR?= NIOyNZdUSU6JRWK=
HH NHfpOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17yfGlEPTB;M{WuNFYhdk1? M4O4b3NCVkeHUh?=
CAL-27 NGLv[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX75N4tQUUN3ME2zOU4yPiCwTR?= NGnJZZNUSU6JRWK=
NEC8 NYHCUoVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1niUGlEPTB;M{WuN|chdk1? NF\WepFUSU6JRWK=
BxPC-3 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDOTWM2OD1|Nj65NUBvVQ>? NIezZmpUSU6JRWK=
SNB75 NX:xUJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjkRVlOUUN3ME2zO{4zPCCwTR?= NU\MXoVxW0GQR1XS
NB13 NX\zSI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W0cmlEPTB;M{iuNlMhdk1? NEG5Z2hUSU6JRWK=
SK-OV-3 NIryR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXObYlKSzVyPUO4Mlc1KG6P NHXBOXRUSU6JRWK=
ME-180 NVTsWnhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXZfmFKSzVyPUO4Mlghdk1? Mlm4V2FPT0WU
JiyoyeP-2003 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN7LkO4JI5O MoHTV2FPT0WU
LU-134-A MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKzZW9PUUN3ME20NE4xOiCwTR?= M1zNSHNCVkeHUh?=
LS-123 M1XPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j6S2lEPTB;NECuNlghdk1? NUfvU4l7W0GQR1XS
COLO-800 M2HKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;HcmlEPTB;NECuOVYhdk1? MYXTRW5ITVJ?
LB831-BLC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7BTWM2OD12MT64OUBvVQ>? Mkn1V2FPT0WU
NCI-H747 M334cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\0TWM2OD12Mj6yPEBvVQ>? MYnTRW5ITVJ?
MZ7-mel M3\Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjETGpKSzVyPUSyMlY3KG6P MXrTRW5ITVJ?
GT3TKB NFXhcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHtTWM2OD12Mj63NkBvVQ>? MXrTRW5ITVJ?
MOLT-16 NEjSOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\oNGpKSzVyPUSzMlA2KG6P M163[HNCVkeHUh?=
23132-87 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfESndKSzVyPUSzMlA2KG6P NG\Bd2dUSU6JRWK=
PF-382 M3zZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGewbm5KSzVyPUS0MlIzKG6P M{fsNnNCVkeHUh?=
ES3 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX2WWtzUUN3ME20OE43KG6P MmHPV2FPT0WU
SW756 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYeyTY9JUUN3ME20OU4yPCCwTR?= M4DreXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 15 mg/mL (56.99 mM)
Water 14 mg/mL warmed (53.19 mM)
Ethanol <1 mg/mL
In vivo water warming 14mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID